Brazil

Brazil has solidified its position as the largest pharmaceutical market in Latin America and the ninth-largest globally, driven by a robust demand for generic drugs and biosimilars.

The nation's life sciences ecosystem is anchored by ANVISA, a world-class regulatory agency known for modernizing approval pathways for advanced therapies and medical devices.

In the realm of biotechnology, Brazil is a pioneer in genomic research and precision medicine, spearheaded by large-scale public initiatives like the Genomas Brasil Program.

The country's healthcare innovation is further fueled by the integration of artificial intelligence (AI) in drug discovery and the growth of Software as a Medical Device (SaMD).

Brazil's academic research sector, supported by prestigious institutions and clinical trial hubs, offers a high-yield environment for multicenter clinical studies.

Furthermore, the medical device market is expanding rapidly, with a strategic focus on digital health solutions and point-of-care diagnostics.

Global investors are increasingly drawn to Brazil's Health Economic-Industrial Complex (CEIS), which incentivizes local production and technological sovereignty.

With a diverse patient population and an aging demographic, the country provides a unique landscape for tackling non-communicable diseases (NCDs) and infectious disease research.

As a leader in agricultural biotechnology, Brazil also leverages its immense biodiversity to drive breakthroughs in biopharmaceuticals and sustainable biological solutions.

This multifaceted approach ensures that Brazil remains a critical destination for global life sciences collaboration and market access in 2026.